The single-arm phase II LUMINOSITY trial (N = 161) enrolled patients with locally advanced or metastatic squamous or non-squamous NSCLC whose tumors were c-MET overexpressed by central immunohistochemistry to receive second- or third-line treatment with Teliso-V 1.9 mg/kg every 2 weeks. This evidence concerns the gene MET and non-small cell lung carcinoma.